12,500 Shares in Solventum Corporation $SOLV Acquired by Maven Securities LTD

Maven Securities LTD purchased a new position in Solventum Corporation (NYSE:SOLV) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,500 shares of the company’s stock, valued at approximately $912,000.

Other institutional investors have also added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC bought a new stake in shares of Solventum during the third quarter valued at approximately $25,000. CYBER HORNET ETFs LLC bought a new position in shares of Solventum during the second quarter worth $28,000. Deseret Mutual Benefit Administrators boosted its position in shares of Solventum by 78.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after acquiring an additional 163 shares during the last quarter. MUFG Securities EMEA plc purchased a new position in Solventum during the second quarter valued at $31,000. Finally, State of Wyoming purchased a new position in Solventum during the second quarter valued at $33,000.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SOLV. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Wells Fargo & Company cut their price objective on Solventum from $86.00 to $83.00 and set an “equal weight” rating for the company in a research report on Friday, February 27th. UBS Group reaffirmed a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, Stifel Nicolaus increased their price target on Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Seven investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, Solventum has an average rating of “Moderate Buy” and an average target price of $93.70.

Solventum Price Performance

Solventum stock opened at $68.64 on Wednesday. Solventum Corporation has a 52-week low of $60.70 and a 52-week high of $88.20. The company has a quick ratio of 0.89, a current ratio of 1.23 and a debt-to-equity ratio of 1.00. The firm’s fifty day moving average is $75.84 and its 200 day moving average is $75.94. The company has a market cap of $11.91 billion, a price-to-earnings ratio of 7.74, a PEG ratio of 1.10 and a beta of 0.40.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, February 26th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The business had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.96 billion. During the same period last year, the company posted $1.41 EPS. The business’s revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Sell-side analysts forecast that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum declared that its Board of Directors has approved a share buyback program on Thursday, November 20th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 7.5% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In related news, Director Amy Mcbride Wendell purchased 1,475 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was bought at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the transaction, the director owned 5,039 shares in the company, valued at approximately $342,803.17. The trade was a 41.39% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.05% of the company’s stock.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.